Steven Taylor

Steven Taylor has extensive experience in the field of drug discovery and development. Steven has worked for four companies, beginning with Boehringer Ingelheim in 2004. There, they held various positions, including Executive Director, Director, Senior Associate Director, Principal Scientist, and Senior Scientist. In 2017, they moved to VL45 Inc (ProtoCo to Kintai Therapeutics) as Vice President Research. At Kintai Therapeutics, they held the roles of Senior Vice President Research and Innovation & Interim Head of Preclinical Development, Senior Vice President, Research and Innovation, and Vice President Research. Currently, they are employed at Skyhawk Therapeutics, where they serve as Head of Business Development and Senior Vice President, Program Development.

Steven Taylor began their educational journey in 1994 when they obtained a BS in Chemistry/Biology from the State University of New York at Fredonia. Steven then went on to obtain a PhD in Chemistry from the University of North Carolina at Chapel Hill in 2002. Following this, they completed a Postdoctoral in Chemical Biology from Harvard University in 2004. In addition to their formal education, Steven Taylor also obtained a Real Estate Contracts certification from LinkedIn in February 2022 and an Algorithmic Trading and Stocks Essential Training certification from LinkedIn in December 2020.